DexCom (DXCM) Stock Forecast, Price & News

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DXCM shares.
View DXCM analyst ratings or view top-rated stocks.

14 Wall Street research analysts have issued 1-year price targets for DexCom's stock. Their DXCM share price forecasts range from $114.00 to $160.00. On average, they anticipate the company's stock price to reach $136.31 in the next year. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for DXCM or view top-rated stocks among Wall Street analysts.

DexCom's stock was trading at $113.24 at the beginning of 2023. Since then, DXCM stock has decreased by 21.7% and is now trading at $88.62.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our DXCM earnings forecast.

DexCom, Inc. (NASDAQ:DXCM) released its quarterly earnings data on Thursday, July, 27th. The medical device company reported $0.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.22 by $0.12. The medical device company had revenue of $871.30 million for the quarter, compared to analysts' expectations of $841.16 million. DexCom had a net margin of 11.18% and a trailing twelve-month return on equity of 22.01%. The company's revenue for the quarter was up 25.2% compared to the same quarter last year. During the same quarter last year, the company posted $0.17 EPS.
Read the conference call transcript.

ETFs with the largest weight of DexCom (NASDAQ:DXCM) stock in their portfolio include First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Subversive Mental Health ETF (SANE), Global X Internet of Things Thematic ETF (SNSR), American Century Mid Cap Growth Impact (MID), Fidelity Digital Health ETF (FDHT), iShares U.S. Medical Devices ETF (IHI), Global X Telemedicine & Digital Health ETF (EDOC) and Neuberger Berman Disrupters ETF (NBDS).

DexCom shares split on the morning of Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were issued to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

DexCom issued an update on its FY 2023 earnings guidance on Friday, September, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.50 billion-$3.55 billion, compared to the consensus revenue estimate of $3.54 billion.

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

DexCom's stock is owned by a number of institutional and retail investors. Top institutional investors include Bank Julius Baer & Co. Ltd Zurich (12.21%), Baillie Gifford & Co. (4.31%), Sands Capital Management LLC (3.38%), Capital Research Global Investors (2.35%), Geode Capital Management LLC (2.21%) and Jennison Associates LLC (1.88%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Bridgette P Heller, Chad Patterson, Jacob Steven Leach, Jay S Skyler, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Matthew Vincent Dolan, Michael Jon Brown, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends.

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DXCM stock can currently be purchased for approximately $88.62.

DexCom (NASDAQ:DXCM) has a market capitalization of $34.37 billion and generates $3.20 billion in revenue each year. The medical device company earns $341.20 million in net income (profit) each year or $0.86 on an earnings per share basis.

The company employs 7,600 workers across the globe.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.